SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharma gets USFDA’s nod for manufacturing facility in Andhra

26 Dec 2015 Evaluate

SMS Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) for its manufacturing facility located at Kandivalasa village in Vizianagaram district of Andhra Pradesh. The USFDA had conducted inspection of the plant in the third week of April this year.

SMS Pharmaceuticals is engaged in manufacturing of active pharmaceutical ingredients (API) and currently has four production facilities and two research centers in operation.

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×